KUALA LUMPUR, March 4 (Bernama) -- Cirrus Therapeutics, a global ocular immunology company, announced several business and pipeline updates to support its strategy of advancing first-in-class and best-in-class therapies for chronic blinding diseases.
The updates include expanding its global footprint to Singapore, forming a strategic partnership with the Agency for Science, Technology and Research (A*STAR), and unveiling a next-generation retinal pigment epithelium (RPE) cell therapy as its second pipeline programme.
“Our presence in Singapore well positions us to leverage critical research, clinical development and partnering opportunities in the Asia-Pacific region.
“We look forward to collaborating with A*STAR Institute of Molecular and Cell Biology (IMCB) and renowned clinician-scientist Dr Xinyi Su to accelerate advancement of cutting-edge ocular medicines, including our differentiated next-generation RPE cell therapy,” said Cirrus Therapeutics Chief Executive Officer and Co-founder, Ying Kai Chan in a statement.
The company established a new research and development (R&D) site in Singapore, expanding its infrastructure beyond its United Kingdom science origins and United States presence, gaining access to the Asia-Pacific biopharma market. Si Hui Tan, who previously led the first-in-class liver regeneration programme at Lerna Biopharma, has been appointed as Director, Pipeline and Site Head, Singapore.
Related to the expansion, Cirrus entered into a multi-million dollar strategic collaboration with Singapore’s A*STAR. This partnership is aimed at accelerating the advancement of innovative ophthalmic assets, including Cirrus’ newly unveiled second pipeline programme. The collaboration will be led by A*STAR IMCB Executive Director, Dr Su.
Cirrus unveiled its second pipeline programme, a novel RPE cell therapy designed for the treatment of centre-involving geographic atrophy (GA). This next-generation cell therapy is differentiated, offering the potential for class-leading vision restoration due to its capacity to function and survive in the hostile GA environment.
The company also continues to advance its lead programme—a novel ocular gene therapy aimed at restoring IRAK-M to prevent age-related macular degeneration (AMD) progression and preserve central vision.
-- BERNAMA
No comments:
Post a Comment